Dave Glidden, PhD, MS
Professor
Epidemiology & Biostatistics
School of Medicine

415-476-1111 ext. 13603

My work focuses on the prevention and treatment of HIV infection.

Show full bio (160 words) Hide full bio

I have been involved in studies of HIV prevention (specifically, truvada for PrEP) for over 12 years. I was the statistician for the iPrEx trial -- the first trial to report the efficacy of oral PrEP and worked on the drugs approval by the FDA. My current work involves studies of the global scale-up of PrEP, innovative designs/statistical analyses of new PrEP agents, and pharmacologic markers of PrEP exposure.

I also collaborate on studies on the outcomes of HIV treatment in resource limited settings. In these settings many patients are absent from clinics. This data requires handling several statistical issues including clustering, competing risk/multiple outcomes, time-dependent covariates and informative censoring. My colleagues and I have pioneered sampling based approaches to losses to follow-up which have given rigorous information about treatment outcomes.

I also collaborate for groups in neurology, pediatrics, LGBT health and nephrology and teach in my department's MCR and Ph.D. program.

Education & Training

Show all (4) Hide

  • Diversity, Equity, and Inclusion Champion Training University of California 10/2020
  • Biostatistics Harvard School of Public Health 12/1995
  • Ph.D. Biostatistics University of Washington 12/1993
  • B.A. Statistics University of California 05/1988

Interests

Show all (10) Hide

  • LGBT health
  • Clinical trials
  • Competing risks
  • Survival analysis
  • HIV pre-exposure prophylaxis
  • HIV prevention
  • HIV treatment
  • Multiple events
  • Biostatistics
  • Causal Inference

Grants and Projects

Show all (4) Hide

Publications (298)

Top publication keywords:
Homosexuality, MaleMedication AdherencePre-Exposure ProphylaxisAdenineTransgender PersonsEmtricitabineHIV InfectionsData Interpretation, StatisticalAnti-Retroviral AgentsChemopreventionEquivalence Trials as TopicAnti-HIV AgentsAza CompoundsTenofovirLost to Follow-Up

Show all (293 more) Hide